PLATINUM Partner

GeneMedicine

GeneMedicine, Co. Ltd. is a research-based biotechnology company focused on developing and commercializing tumor-targeted and systemically deliverable oncolytic adenovirus for the treatment of intractable cancers. Our research programs utilize novel and innovative adenoviral vector platforms, which can selectively lyse cancer cells, express numerous combinations of therapeutic transgenes at a high level, induce robust antitumor immune response, and deliver systemically. The company’s key pipelines are based on oncolytic adenovirus against solid tumors (GM 101), pancreatic cancers (GM102), and metastatic lung and liver cancers (GM 103).

 

GeneMedicine’s key oncolytic adenovirus platforms leverage the unique characteristics, such as high gene transfer efficiency, viral replication capacity, and oncolytic activity, of adenovirus to maximize the anticancer effect. These state-of-the-art platforms are culmination of over two decades of extensive and rigorous research development process. Thus, these platforms possess several unique core technologies that supersede various aspects of competing viral platforms. Further, our major platforms possess unique set of therapeutic transgenes to offer specialized solution to various intractable cancer types. Importantly, we continue to perfect the cancer specificity, safety profile, therapeutic transgene expression, and antitumor effect of our platforms, striving to bring these innovative solutions to cancer patients worldwide and surpass the limitations of conventional therapies.

Oncolytics Biotech Inc.

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype - turning "cold" tumors "hot" - through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer.

Psioxus

Smart Science for Serious Disease

PsiOxus aims to be the world’s leading immuno-oncolytic virus company, delivering medicines of value to patients with cancer.

Our work is product and platform based with a focus on discovering and developing innovative immunotherapies for the treatment of solid tumors. Our products utilize enadenotucirev, our proprietary first generation oncolytic virus and our proprietary platform technology for next generation oncolytic viruses, Tumor-Specific Immuno-Gene Therapy (T-SIGn).

Our world leading scientists and highly experienced management team are based in Oxford, UK and Philadelphia, USA.

GOLD Partner

ASGCT

ASGCT is the primary membership organization for scientists, physicians, patient advocates, and professionals involved in gene and cell therapy. The Society’s mission is to advance knowledge, awareness, and education leading to discovery and clinical application of gene and cell therapies to alleviate disease. ASGCT also publishes the Molecular Therapy family of journals, including Molecular Therapy – Oncolytics, an online open-access journal focusing on the development and clinical testing of viral, cellular, and other biological therapies targeting cancer.

Replimune

Oncolytic immunotherapy is an emerging class of cancer therapeutics which exploit the ability of viruses to selectively replicate in and kill tumor tissue, while at the same time inducing a potent, patient-specific, anti-tumor immune response. Oncolytic viruses have the unique ability to generate a systemic immune response to the patient’s particular complement of tumor antigens, including neoantigens, with a truly off-the-shelf and practical approach. This potentially solves a current ‘holy grail’ of immune-oncology research, i.e. the development of truly practical patient-specific tumor neoantigen vaccines. Oncolytic viruses also potently activate innate immunity, including through TLRs and STING, meaning that altogether oncolytic immunotherapies bundle multiple immune oncology approaches into one. This particularly the case if, as for Replimune’s products, these are then used to also deliver multiple therapeutic proteins to tumors too.

SILVER Partner

ABL, Inc.

ABL, Inc. is a CMO/CRO with facilities in the US and Europe that provides diverse services for biologics development and manufacturing (protein and viral). ABL offers PD, GMP manufacturing, preclinical and clinical development, comprehensive immunological services, clinical immunogenicity testing, GCLP trial sample processing and testing among other services.

AMGEN

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives.

OncoMyx Therapeutics

OncoMyx Therapeutics, a startup launched from Professor Grant McFadden’s laboratory at Arizona State University (ASU), develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response and treat cancer. The company’s MYXV platform is poised to be a best-in-class oncolytic virus (OV) approach, and the top OV development team has assembled around MYXV to create important new therapeutic options for cancer patients.  OncoMyx has raised a $25M series A to advance development of its lead OV therapeutic program for the treatment of various cancers. 

Turnstone

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. The company’s first-of-its-kind investigational oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, with the goal of preventing recurrence and delivering a cure. Turnstone Biologics’ robust pipeline of early-stage investigational therapies, based on its Maraba (MG1) oncolytic virus platform, are in development for solid tumors. In addition to the MAGEA3 therapy currently in the clinic, Turnstone Biologics expects to enter the clinic in early 2018 with a therapy for HPV+ cancers, and is also developing medicines for multiple other cancers. These immunotherapies are being evaluated as monotherapies and in combination with other cancer therapies, including checkpoint inhibitors. Turnstone has been financed by Versant Ventures, OrbiMed, F-Prime Capital Partners and FACIT. Turnstone recently entered a research, option and license agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company, whereby AbbVie obtained an exclusive option to license up to three of Turnstone’s next-generation oncolytic viral immunotherapies

Western Oncolytics

Western Oncolytics, a privately held biotechnology company, is developing a new generation of optimized, multi-mechanistic cancer immunotherapies. The company’s oncolytic vaccinia virus immunotherapies are designed with proprietary, synergistic combinations of genetic modifications to systemically target and destroy cancer cells while enhancing patients’ anti-tumor immune response. Western Oncolytics is committed to creating a best-in-class immuno-oncology platform to help patients across the globe beat cancer.